Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No short-term benefit with gender-specific knees?

This article was originally published in The Gray Sheet

Executive Summary

Study of 85 women receiving a standard Zimmer NexGen LPS-Flex prosthesis in one knee and a Zimmer Gender Solutions gender-specific prosthesis in the other knee found that 84% of the patients felt there was no difference in either implant, according to an article published Aug. 18 in Journal of Bone and Joint Surgery. The mean postoperative Knee Society Score after two years was 95.5 points in the standard group and 96.5 point in the gender-specific group. Range of motion in the groups while lying down also was similar (125 degrees for the standard knee and 126 degrees in the gender-specific implant). However, the authors, led by Young-Hoo Kim, The Joint Replacement Center of Korea, note that "longer follow-up is needed." Zimmer, Smith & Nephew and Wright Medical are among firms offering gender-specific knees

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts